Biologics Sales in 2010 exceeded US$ 100 bln
- Category: Press Room
- Published on Wednesday, 16 March 2011 09:25
- Hits: 9219
Growth drivers were therapeutic antibodies; single digit growth for most therapeutic proteins; novel anti-inflammatory antibodies continue strong growth; number of blockbuster biologics increased to 30
Sitges, Spain | March 7, 2011 | The Business Intelligence firm La Merie S.L. released its new compilation of biologics sales in 2010. In its fifth edition, the report revealed that 2010 sales of mainly recombinant therapeutic proteins and antibodies exceeded US$ 100 bln (from US$ 92 bln in 2009 to US$ 108 bln in 2010). Growth was mainly driven by therapeutic antibodies (+16% to +33% vs previous year) which accounted for 48% of biologics sales in 2010. Among the therapeutic proteins, double digit growth was reported for insulin and insulin analogs (+17%) and recombinant coagulation factors (+16%), whereas modest growth (4% to 7%) was observed for therapeutic proteins, except for erythropoietin which continued its descent (-3% vs 2009) and FSH products (-1%). The anti-TNF biologic etanercept continued to be the single best selling blockbuster molecule with 2010 sales of US$ 7.287 bln. The insulin analog detemir achieved for the first time blockbuster status and increased together with the neurotoxin Botox the number of blockbuster antibodies and proteins to 30. These results and more were found in an elaboration prepared by La Merie Business Intelligence and published in a complimentary report on March 7, 2011. The document entitled “TOP 30 Biologics 2010” can be acquired as a free download at La Merie’s News Center and Online Store PipelineReview.com (www.pipelinereview.com).
The “TOP 30 Biologics 2010” report presents in tabular format 2010 sales figures 1) of the TOP 30 branded biologic products with more than US$ 1 bln sales; 2) of the 14 top-selling classes of recombinant biologicals, i.e. proteins and antibodies (excluding vaccines and peptides), and in detail the sales figures of the individual products. In addition, information is provided on brand and generic names, target, class of compound, originator and licensee companies, product category and major indications. All information is fully referenced by a hyperlink leading to the original source of information.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.
PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry. FREE R&D Newletters conveniently bring via e-mail a daily or weekly selection of the most interesting news from biopharmaceutical R&D. For more information visit www.pipelinereview.com.